Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (GB:0XOD)
LSE:0XOD
0XOD Stock Chart & Stats
$24.01
-$0.22(-1.95%)
At close: 4:00 PM EST
$24.01
-$0.22(-1.95%)
Day’s Range― - ―
52-Week Range$3.61 - $24.60
Previous CloseN/A
Volume100.00
Average Volume (3M)2.30K
Market Cap
$1.08B
Enterprise Value$960.30M
Total Cash (Recent Filing)$128.38M
Total Debt (Recent Filing)$129.94M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Mar 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding46,808,890
10 Day Avg. Volume3,866
30 Day Avg. Volume2,304
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-51.87
Price to Sales (P/S)5.05
P/FCF Ratio-4.70
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue13.28
Enterprise Value/Gross Profit14.95
Enterprise Value/Ebitda-10.57
Forecast
1Y Price Target
$39.40Price Target Upside64.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial UTOPIA pivotal data confirm UGN-103 clinical impact in-line with ZUSDURI, with the FDA agreeing to the regulatory plan to submit a New Drug Application.
Market DemandUroGen management indicated strong market demand for ZUSDURI, as evidenced by roughly $4.5M in preliminary demand revenue estimated during the month of October 2025 alone.
Operational GrowthThe company plans to leverage its 82 sales reps and 5,500 active Jelmyto prescribers, who treat a significant portion of the LG/IR NMIBC treatment volume.
Bears Say
Financial PerformanceRevenue and earnings miss moderately—lowering price target based on revised sales ramp trajectory.
Urogen Pharma News
0XOD FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest share price was $3.61 and its highest was $24.59 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.08B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Mar 12, 2026 which is in 120 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Nov 06, 2025. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.692 by $0.002.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.48.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 46,808,890 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.692. Following the earnings report the stock price went up 17.005%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in GB:0XOD
Urogen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.40 (64.10% Upside)
$39.40 (64.10% Upside)
Blogger Sentiment
Bullish
GB:0XOD Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $176.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.71%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
0XOD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with strong progress in the ZUSDURI launch and JELMYTO revenue growth, offset by challenges in operational execution and increased expenses. The permanent J-code for ZUSDURI is anticipated to drive future growth, but current operational delays and increased net loss are notable concerns.View all GB:0XOD earnings summaries0XOD Stock 12 Month Forecast
Average Price Target
$39.40
▲(64.10% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Options Prices
Currently, No data available
---